Cancer mTOR Inhibitors Market By Type ( Afinitor/Votubia, Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor, Torisel (Temsirolimus), Evertor andndash ), By Application ( Breast Cancer, Hematological Malignancy, Neuroendocrine Tumors, Hepatocellular Carcinoma, Glioblastoma ), By Stent Size ( 18 mm, 20 mm, 14 mm ), Industry Trends, Estimation & Forecast, 2017 - 2025

April 2018

 Pages: 178

 ERC 8106


Cancer mTOR Inhibitors Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.

mTOR, also called as Mammalian target of rapamycin (mTOR), is a member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases. This Kinase functions as a master switch between catabolic and anabolic metabolism and as such is a target for the design of anticancer agents. With the continuous studies and researches in medical science, It is now well-established that mTOR plays a pivotal role in governing cell growth and proliferation, hence making mTOR a therapeutic target for disease conditions caused by deregulated cell proliferation, such as cancer. Since the past two decades, mTOR inhibitors have been developed dedicatedly and a majority of them are still being used for curing Cancer. The most developed mTOR inhibitor called as rapamycin has depicted considerable response to tumors and has substantially improved the survival of patients suffering with renal cell carcinoma.

On the basis of Geography, North America and Europe have emerged out as the largest markets for these inhibitors, owing to the increased awareness among people and large number of diagnosis done for cancers. As per Centers for Disease Control & Prevention, cancer kills more than half a million Americans. Cancer is the second leading cause of death in the United States. One of every four deaths in the United States is due to cancer. Initiatives taken by governments in EU and North America for the treatment of Cancer is giving a push to the mTOR Inhibitor market.

The report provides detailed qualitative and quantitative analysis of the Cancer mTOR Inhibitors Market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely product and application in each of the major regions.

Cancer mTOR Inhibitors Market Player Analysis -

The report presents detailed analysis of major players operating in Cancer mTOR Inhibitors Market. Few of the include Adimab, Celator Pharmaceuticals, Celgene Corporation, Eli Lilly, Wyeth, Abraxis BioScience, Exelixis, GlaxoSmithKline,HEC Pharm, Intellikine, Novartis, Oneness Biotech, PIQUR Therapeutics, Semafore Pharmaceuticals and Takeda. Detailed coverage on these market players with information on their revenue from Cancer mTOR Inhibitors business, market share, gross margin and their growth strategies have been provided in the report.

Cancer mTOR Inhibitors Market Segmentation

Cancer mTOR Inhibitors market is segmented on the basis of product, application and geography. By type, the market is segmented into Afinitor, Torisel and Others. On the basis of application, the market is categorized as Breast Cancer, glioblastoma and others. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Cancer mTOR Inhibitors Market Segmentation

By Type
   • Afinitor/Votubia
   • Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
   • Torisel (Temsirolimus)
   • Evertor andndash

By Application
   • Breast Cancer
   • Hematological Malignancy
   • Neuroendocrine Tumors
   • Hepatocellular Carcinoma
   • Glioblastoma

By Geography
   • North America
            o U.S.
            o Canada
            o Mexico
   • Europe
            o U.K.
            o France
            o Germany
            o Italy
            o Spain
            o Rest of Europe
   • Asia-Pacific
            o China
            o Japan
            o India
            o Korea
            o Rest of APAC
   • South America
            o Brazil
            o Rest of South America
   • Rest of the World
            o Middle East
            o Africa

Cancer mTOR Inhibitors Market Key Players

• Adimab
• Celator Pharmaceuticals
• Celgene Corporation
• Eli Lilly
• Wyeth
• Abraxis BioScience
• Exelixis
• GlaxoSmithKline
• HEC Pharm
• Intellikine
• Novartis
• Oneness Biotech
• PIQUR Therapeutics
• Semafore Pharmaceuticals
• Takeda

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Cancer mTOR Inhibitors Market in 2017 and the expected market size by 2022, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2022)?
    • Which are the leading companies in the Cancer mTOR Inhibitors Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!